Kang, Yoon-Koo http://orcid.org/0000-0003-0783-6583
Morita, Satoshi
Satoh, Taroh
Ryu, Min-Hee
Chao, Yee
Kato, Ken
Chung, Hyun Cheol
Chen, Jen-Shi
Muro, Kei
Kang, Won Ki
Yeh, Kun-Huei
Yoshikawa, Takaki
Oh, Sang Cheul
Bai, Li-Yuan
Tamura, Takao
Lee, Keun-Wook
Hamamoto, Yasuo
Kim, Jong Gwang
Chin, Keisho
Oh, Do-Youn
Minashi, Keiko
Cho, Jae Yong
Tsuda, Masahiro
Sameshima, Hiroki
Chen, Li-Tzong
Boku, Narikazu
Funding for this research was provided by:
Ono Pharmaceutical
Bristol-Myers Squibb
Article History
Received: 28 April 2021
Accepted: 4 August 2021
First Online: 4 September 2021
Declarations
:
: All authors received grants from Ono Pharmaceutical Co., Ltd., and Bristol-Myers Squibb for the work under consideration for publication. Y-KK reports personal fees from Ono, Bristol-Myers Squibb, Daehwa, Blueprint, Merck, and Astellas, outside the submitted work. MS reports personal fees from Ono, Bristol-Myers Squibb, AstraZeneca, Chugai, Eli Lilly Japan, MSD, Pfizer Japan, and Taiho, outside the submitted work. TS reports personal fees from Ono for the work under consideration for publication; other from Ono (endorsed Department, lecture fee); grants, personal fees, and other from Chugai and Yakult Honsha (endorsed Department, lecture fee); grants and other from Eli Lilly (lecture fee), grants from MSD, Gilead Sciences, Parexel, and Daiichi Sankyo, and Astellas; grants and personal fees from Taiho, personal fees from Takara-Bio, outside the submitted work. M-HR reports honorarium and advisory board fees from Ono, Bristol-Myers Squibb, MSD, Eli Lilly, Taiho, Novartis, Daiichi Sankyo, AstraZeneca, and Daehwa, outside the submitted work. KK reports research funding from Merck & Co., Shionogi, Ono, MSD, Merck Serono, and BeiGene, outside the submitted work. HCC reports grants (research support) from Eli Lilly, GlaxoSmithKline, MSD, Merck Serono, Bristol-Myers Squibb, Ono, Taiho, Amgen, BeiGene, Incyte, and Zymework; personal fees (honoraria) from Merck Serono, Eli Lilly, Foundation Medicine, and Roche; and personal fees (consultation) from Taiho, Celltrion, MSD, Eli Lilly, Quintiles, Bristol-Myers Squibb, Merck Serono, Gloria, BeiGene, Amgen, and Zymeworks, outside the submitted work. J-SC reports personal fees (consultation) from Ono for the work under consideration for publication. KMu reports grants and personal fees from Ono, Sanofi, Taiho, and Amgen; grants from MSD, Daiichi Sankyo, Parexel International, Pfizer, Solasia, and Merck Serono; and personal fees from AstraZeneca, Eli Lilly, Chugai, Takeda, Bristol-Myers Squibb, and Bayer, outside the submitted work. K-HY reports personal fees (honoraria) from Ono, Bristol-Myers Squibb, Boehringer Ingelheim, Takeda, MSD, Eli Lilly, Amgen, and Roche, outside the submitted work. TY reports grants and personal fees (honoraria) from Chugai and Taiho; personal fees (honoraria) from Bristol-Myers Squibb; and personal fees (honoraria and advisory role) from Ono, outside the submitted work. TT reports grants from MSD, Merck Serono, and Chugai; and grants and personal fees from Daiichi Sankyo, Takeda, and Taiho, outside the submitted work. K-WL reports grants from MSD, AstraZeneca/MedImmune, Merck KGaA, Pfizer, BeiGene, ALX Oncology, Zymeworks, MacroGenics, Five Prime Therapeutics, Oncologie, Pharmacyclics, Green Cross Corp, ABLBIO, Y-BIOLOGICS, Genexine, LSK BioPharma, Daiichi Sankyo, Taiho (to his institution for conducting clinical trials), personal fees (consultation) from ISU ABXIS, Bayer and Daiichi Sankyo, outside the submitted work. KC reports personal fees from Ono, Bristol-Myers Squibb, Taiho, and Chugai, outside the submitted work. D-YO reports grants from AstraZeneca outside the submitted work. KMi reports research funding from MSD, Merck Biopharma, Astellas, Taiho., and Daiichi Sankyo, outside the submitted work. HS is an employee of Ono. L-TC reports personal fees from Ono and Bristol-Myers Squibb for the work under consideration for publication; grants from the Ministry of Science and Technology (Taiwan), Ministry of Health and Welfare (Taiwan), grants, personal fees and non-financial support from Novartis (study medication and funding support, and honorarium), grants from Pfizer (study funding), personal fees from Eli Lilly (honorarium), grants from Merck Serono (study funding), grants, personal fees and non-financial support from TTY (study medication and funding support, and honorarium), personal fees from PharmaEngine, Shire, MSD, Bristol-Myers Squibb, and Ono (honorarium), grants from OBI (preclinical testing), grants from Polaris (translational Research funding), grants, personal fees and non-financial support from SynCore (study medication and funding support, and honorarium), grants and non-financial support from Celgene (study medication and funding), and personal fees from Five Prime, and Merrimack’ outside the submitted work. NB reports personal fees from Ono and Bristol-Myers Squibb for the work under consideration for publication; grants and personal fees from Taiho and grants from Takeda, outside the submitted work.
: All procedures followed the ethical standards of the responsible committee on human experimentation (institutional and national) and the Helsinki Declaration of 1964 and later versions.
: Informed consent to be included in the ATTRACTION-2 study was obtained from all patients.